Clinical Trials Browser

Acquired Immunodeficiency Syndrome, Uterine Cervical Dysplasia, Papillomavirus Infections

NCT05291871 2025-03-27

Immunogenicity of Fractional Dose of the HPV Vaccines

Phase 4 Active not recruiting

92 enrolled

Papillomavirus Infections

NCT01824537 2025-03-19

TRAP-HPV

Phase 4 Completed

372 enrolled 12 charts

Papillomavirus Infections

NCT06700941 2024-11-22

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

Completed

8,000,000 enrolled

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT06686043 2024-11-13

HPV-VIM

Phase 2 Recruiting

85 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Papillomavirus Infections

NCT06207175 2024-01-23

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Phase 3 Unknown

1,260 enrolled

Papillomavirus Infections

NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Phase 1 Completed

90 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Phase 2 Completed

780 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Phase 1 Completed

160 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05672966 2023-01-06

Phase I Clinical Trial of a Candidate HPV Vaccine

Phase 1 Unknown

40 enrolled

Papillomavirus Infections

NCT05668572 2023-01-04

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Phase 3 Unknown

12,000 enrolled

Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05173324 2022-08-03

H2VICTORY

Phase 3 Not yet recruiting

8,000 enrolled

HIV Infections, Papillomavirus Infections

NCT00231413 2019-12-12

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Phase 2 Completed

383 enrolled 30 charts

Papillomavirus Infections

NCT04171505 2019-11-21

VENUS

Unknown

508 enrolled

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT00309166 2018-09-17

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Phase 2 Completed

270 enrolled 14 charts

Papillomavirus Infections

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Phase 1 Completed

961 enrolled 43 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

744 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01984697 2018-08-08

V503-010

Phase 3 Completed

1,518 enrolled 44 charts

Papillomavirus Infections

NCT00552279 2018-06-25

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Phase 3 Completed

805 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Phase 3 Completed

600 enrolled 12 charts

Papillomavirus Infections

Clinical Trials

AGO-Gard

Immunogenicity of Fractional Dose of the HPV Vaccines

TRAP-HPV

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

HPV-VIM

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Phase I Clinical Trial of a Candidate HPV Vaccine

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

H2VICTORY

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

VENUS

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

V503-010

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)